Abstract
Long‐term survival after definitive concurrent chemoradiotherapy (dCCRT) remains limited in locally advanced esophageal squamous cell carcinoma (ESCC). We evaluated induction immunochemotherapy followed by dCCRT and consolidation immunotherapy in this setting. This prospective, single‐arm Phase II study enrolled 54 adults selected for definitive nonsurgical treatment. The planned regimen comprised two cycles of induction immunochemotherapy with nab‐paclitaxel, carboplatin, and a programmed cell death protein 1 (PD‐1) inhibitor, followed by dCCRT with 50.4 Gy in 28 fractions and concurrent weekly chemotherapy. The same PD‐1 inhibitor was planned as consolidation therapy for up to 1 year. The primary endpoint was the 2‐year overall survival (OS) rate. Fifty‐three patients (98.1%) completed two induction cycles, all 54 proceeded to dCCRT, and 31 (57.4%) received consolidation immunotherapy. Among all 54 enrolled patients, the 2‐year OS and progression‐free survival (PFS) rates were 84.6% (95% confidence interval [CI], 75.2%–95.0%) and 61.5% (95% CI, 49.5%–76.4%), respectively, after a median follow‐up of 28.1 months. Adverse events occurred predominantly during dCCRT and were mainly hematologic; lymphopenia and esophagitis were among the most frequent toxicities. Exploratory analyses suggested that suboptimal response after induction immunochemotherapy was associated with shorter PFS. The survival outcomes observed with this sequential approach support further evaluation of its comparative clinical benefit in randomized studies. Trial Registration: ClinicalTrials.gov (NCT05621707)
Funding Information
  • Wu Jieping Medical Foundation (320.6750.2022‐09‐9)

This publication has 14 references indexed in Scilit: